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Abstract Regorafenib is an oral multikinase inhibitor that has
shown antitumor activity in a range of solid tumors. Based on
data from phase III clinical trials, regorafenib is indicated for
the treatment of adult patients with metastatic colorectal can-
cer who have previously been treated with, or are not consid-
ered candidates for, other available therapies, and in patients
with advanced gastrointestinal stromal tumors that cannot be
surgically removed and no longer respond to other appropriate
treatments. A panel of oncology nurses, research coordinators,
and other medical oncology experts, experienced in the care of
patients treated with regorafenib, met to discuss the best
practice for the management of regorafenib-associated ad-
verse events (AEs). The panel agreed that, in clinical trials
and daily practice with regorafenib, AEs are common but
mostly manageable. The most common and/or important
AEs associated with regorafenib were considered to be
hand–foot skin reaction, rash or desquamation, stomatitis,
diarrhea, hypertension, liver abnormalities, and fatigue. This
manuscript describes the experience and recommendations of
the panel for managing these AEs in everyday clinical prac-
tice. Appropriate education, monitoring, and management are
considered essential for reducing the incidence, duration, and
severity of regorafenib-associated AEs.
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Introduction
Regorafenib (Stivarga, Bayer HealthCare Pharmaceuticals) is
a novel, orally administered multikinase inhibitor [1]. Preclin-
ical studies demonstrated that regorafenib targets cell-
signaling pathways involved in tumor formation and progres-
sion, including inhibition of protein kinases associated with
angiogenesis (e.g., VEGFR1–3 and TIE2), oncogenesis (e.g.,
KIT and RET), and maintenance of the tumor microenviron-
ment (e.g., PDGFR and FGFR) [1]. The potential value of
regorafenib in humans has been studied in a program of
clinical trials, following phase I evidence of tolerability and
preliminary antitumor activity in patients with a range of
advanced solid tumors [2].
Regorafenib is indicated (pending marketing authorization
in some countries) for the treatment of adult patients with
metastatic colorectal cancer (mCRC) who have previously
been treated with, or are not considered candidates for, other
available therapies, and in patients with advanced gastrointes-
tinal stromal tumors (GISTs) that cannot be surgically
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removed and no longer respond to other appropriate treat-
ments [3–6]. The recommended dose of regorafenib is
160mg to be taken once daily for 3weeks, followed by 1week
off therapy. This 4-week period is considered a treatment
cycle. Treatment should be continued for as long as benefit
occurs or until unacceptable toxicity is experienced. Of note,
regorafenib is metabolized byCYP3A4 and UGT1A9 [7]. Co-
administration of strong CYP3A4 inducers (e.g., rifampin and
phenytoin) and strong CYP3A4 inhibitors (e.g. ,
clarithromycin, grapefruit juice, and itraconazole) should be
avoided. Co-administration of regorafenib may increase sys-
temic exposure to UGT1A1 and UGT1A9 substrates (e.g.,
SN-38, an active metabolite of irinotecan and a substrate of
UGT1A1).
The applications for marketing authorization of regorafenib
in mCRC and GISTwere based on data from two internation-
al, randomized, phase III trials of regorafenib, named COR-
RECT (a double-blind, placebo-controlled study of regorafe-
nib plus best supportive care [BSC] versus placebo plus BSC
in patients with mCRC that had progressed after standard
therapy) and GRID (a double-blind, placebo-controlled study
of regorafenib plus BSC versus placebo plus BSC for patients
with metastatic and/or unresectable GIST whose disease had
progressed despite prior treatment with at least imatinib and
sunitinib) [8–11].
In the CORRECTstudy, 760 patients were randomized in a
2:1 ratio to receive regorafenib or placebo [9]. The primary
study endpoint was overall survival—this endpoint was met at
a planned interim analysis, with a hazard ratio (HR) of 0.77
(95 % confidence interval [CI] 0.64–0.94; one-sided p =
0.0052) for overall survival with regorafenib versus placebo
(median, 6.4 versus 5.0 months, respectively). Patients
assigned to the regorafenib group received 78.9 % of the
planned dose during the study, and dose modifications were
required in 378 of 500 patients (76 %). The placebo group
received 90.1 % of the planned dose, and 97 of 253 patients
(38 %) required dose modification. The most common reason
for dose modification was adverse events (AEs), with 67 % of
regorafenib patients and 23 % of placebo patients experienc-
ing AEs leading to dose modification. The most common
grade 3 or higher regorafenib-related AEs were hand–foot
skin reaction (HFSR; 46.6 %, all grades; 16.6 %, grade 3;
and grade 4, not applicable), fatigue (47.4 %, all grades;
9.2 %, grade 3; 0.4 %, grade 4), hypertension (27.8 %, all
grades; 7.2 %, grade 3; and 0 %, grade 4), and diarrhea
(33.8 %, all grades; 7.0 %, grade 3; and 0.2 %, grade 4).
The GRID study randomized 199 patients in a 2:1 ratio to
receive regorafenib or placebo [11]. According to an indepen-
dent, blinded central review, median progression-free survival
(primary endpoint) was 4.8 months with regorafenib and
0.9 months with placebo (HR, 0.27; 95 % CI, 0.19–0.39; p
<0.0001). Because of the high rate of crossover (85 % of the
placebo group crossed over on disease progression to receive
open-label regorafenib), the overall survival results from
GRID did not reach statistical significance. Patients in the
regorafenib group received 78.0 % of the planned dose and
patients in the placebo group received 83.8 % of the planned
dose. Drug-related AEs were reported for 98 % of patients
receiving regorafenib and 68 % of patients receiving placebo,
the most common being HFSR (56.1 %, all grades; 19.7 %,
grade 3; grade 4, not applicable), hypertension (48.5 %, all
grades; 22.7%, grade 3; and 0.8%, grade 4), diarrhea (40.2%,
all grades; 5.3 %, grade 3; and 0 %, grade 4), and fatigue
(38.6 %, all grades; 2.3 %, grade 3; and 0 %, grade 4).
Following these trials, an open-label phase IIIb study of
regorafenib in patients with mCRC that had progressed after
standard therapy was established [12]. This prospective, mul-
ticenter, single-arm, interventional, expanded-access study
(named CONSIGN) will provide regorafenib to patients with
mCRC that has failed standard therapies, for whom no treat-
ment alternatives are available, in the time between the posi-
tive phase III results and approval or availability of regorafe-
nib locally. The study aims to collect additional safety data on
regorafenib. The primary endpoint is safety, and patients will
continue on treatment until reaching one of the main criteria—
death, unacceptable toxicity, patient's withdrawal of consent,
treating physician's decision that discontinuation of treatment
is in the patient's best interest, or substantial noncompliance
with the protocol. The study is ongoing.
Experience to date shows that regorafenib can provide
survival benefits in patients with mCRC or advanced GIST,
but that AEs are common and can necessitate dose modifica-
tion. The AE profile of regorafenib was consistent across both
phase III studies—HFSR, fatigue, diarrhea, and hypertension
were the most common drug-related AEs [9, 11]. In our
experience, while other AEs (e.g., nausea and anorexia) may
also occur, they do not have an impact on patients' quality of
life to the extent that those covered in this manuscript may do,
and do not tend to require treatment modification.
We noticed that the AEs of targeted therapies are often
compared with AEs of chemo- and radiation therapy, rather
than with the AEs of hormonal therapy. However,
chemotherapy-associated AEs are cumulative, while most
AEs associated with hormonal therapy appear and, if ade-
quately managed, may resolve within the first 12 weeks of
treatment—similar to most regorafenib-associated AEs.
Sound knowledge of the AE profile associated with rego-
rafenib and proactive AE monitoring and management can
help patients to better tolerate the drug and optimize treatment
outcome.
Objective
A panel of medical oncology experts from Europe and Can-
ada, experienced in the care of patients treated with
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regorafenib, met to discuss the best practice for the manage-
ment of regorafenib-associated AEs. The agenda for the day
was developed by the meeting chair (Mieke De Wit) and
included a detailed discussion of the most common AEs
among patients receiving regorafenib and the personal expe-
rience of the expert panel in the management of these events.
The meeting was supported by Bayer HealthCare Pharmaceu-
ticals, which funded Succinct Healthcare Communications to
manage logistics and provide medical-writing support. This
manuscript presents the experience and recommendations of
the group and communicates the AE management consider-
ations that we believe to be the most important for maintaining
quality of life and adherence to treatment in patients receiving
regorafenib.
Management strategy for regorafenib-related AEs
HFSR
The three grades of HFSR, according to the National Cancer
Institute Common Terminology Criteria for Adverse Events
(CTCAE) version 4.03, are described in Table 1 [13]. Report-
ed in around half of the patients receiving regorafenib, HFSR
was the most common AE in the CORRECT and GRID
studies [9, 11].
HFSR is characterized by localized hyperkeratotic lesions
that may be surrounded by erythematous regions within the
skin. The areas of the skin under the most pressure or flexure
are most likely to be affected, such as the palms of the hand,
fingertips, finger webs, distal phalanges, soles of the feet, and
toes [14]. HFSR usually occurs early (within 4 weeks of
initiation of regorafenib treatment; most commonly within
the first 2 weeks) [14, 15], and, although it is not life threat-
ening and usually resolves with appropriate management, it
can negatively affect patients' quality of life physically, psy-
chosocially, and socially [16].
As with many potential AEs, early detection and prompt
initiation of therapeutic management can reduce the severity
and duration of HFSR [14]. Close monitoring is crucial—
during the first two cycles of treatment, we recommend that
patients should be assessed for HFSR weekly by a healthcare
provider; from cycle 3 onwards every 4 weeks. It is important
to encourage patients and caregivers to monitor for potential
symptoms of HFSR and to maintain frequent communication
between the patient and healthcare provider to ensure that
symptoms are detected and managed at the earliest possible
stage.
Preventive measures can decrease the likelihood of patients
experiencing HFSR [14]. A full-body skin examination
should be carried out before treatment initiation to ensure that
any changes can be accurately noted, and any calluses should
be softened and removed before and during treatment.
It is important that patients understand the best practices for
managing HFSR and what actions to take at home to prevent
or manage the occurrence. Care should be taken to avoid
pressure and friction on the skin. The patient should be ad-
vised to avoid traumatic activity to minimize stress on the
skin. The pressure points and pressure-sensitive areas on the
feet can be protected with cotton socks, well-padded and well-
fitting shoes, foam-padded soles, and insole cushions. Padded
gloves should be worn when using tools that might damage
the skin on the hands. Effective use of creams and moistur-
izers can help to maintain the condition of the skin. Soaps and
hand sanitizers containing alcohol and the use of hot water can
dry the skin and should be avoided. If HFSR is painful,
patients should be advised to cool the skin with cold packs
and to treat with analgesics such as nonsteroidal anti-
inflammatory drugs.
If active management does not alleviate HFSR symptoms,
dose modification may be required and usually leads to rapid
alleviation of symptoms (within 1–2 weeks) [14]. We believe
that the regorafenib trial protocols contain effective advice on
the management of HFSR, including details of appropriate
dose modifications when necessary [9, 11]. These recommen-
dations, along with the typical manifestations of symptoms,
preventive measures, and suggested topical treatments are
shown in Table 2. With these measures, HFSR is usually
resolved or effectively controlled—Fig. 1 shows examples
of HFSR in patients being treated with regorafenib and how
the reaction can be resolvedwith appropriate management and
dose modification.
Rash or desquamation
Maculopapular rash is a disorder characterized by the presence
of macules (flat, discolored areas of skin) and papules (solid
elevations of skin), with symptoms including photosensitivity,
erythema, dry or peeling skin, blistering, and pruritus [17]. The
grading of rash, as described in Table 1, is according to body-
surface coverage—macules or papules covering less than 10 %
of body surface are grade 1, covering 10–30 % are grade 2, and
covering more than 30 % are grade 3 [13]. In our experience,
grades 1–2 rash is most common among patients receiving
regorafenib, whereas grade 3 is less common. Regorafenib-
related rash or desquamation of any grade was experienced
by 26% of the patients receiving regorafenib in the CORRECT
trial (incidence of grade 3 was 6 %) and by 18 % of the patients
in the GRID trial (grade 3, 2 %) [9, 11]. Regorafenib-associated
rash predominantly occurs within the first cycle and the inci-
dence is considerably reduced in subsequent cycles.
With appropriate management, and dose modification
where necessary, rash is normally resolved. We recommend
that, during the first two cycles, patients should be monitored
for rash every week, in combination with the HFSR assess-
ment, with the frequency decreasing to every 4 weeks from
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cycle 3. Preventive measures, such as regular use of emol-
lients (not containing alcohol) from initiation of treatment, the
use of mild soaps, and avoidance of extreme temperatures and
direct sun exposure, can help to prevent or reduce the severity
of rash. Rash, in all three grades, can be effectively managed
with antihistamines and a short treatment with dermatology
ointments containing class IV corticosteroids (e.g., clobetasol
propionate 0.05 % in cold cream)—a dermatologist should be
consulted to determine the most appropriate treatment.
Stomatitis
Stomatitis, also referred to as oral mucositis, is the inflamma-
tion of the mucous lining of any of the structures in the mouth
and oropharynx. The CTCAE version 4.03 describe five
grades (see Table 1) [13]. Regorafenib-associated stomatitis
is a common AE [9, 11] and tends to occur between 5 and
14 days after the start of a treatment cycle. In our experience,
the effect may occur in cycle 1 only or may be recurrent, and
Table 1 NCI CTCAE version 4.03 grading for regorafenib-associated adverse events [13]
Grade 1 Grade 2 Grade 3 Grade 4 Grade
5
HFSR (palmar-
plantar
erythrodysesth-
esia syndrome)
Minimal skin changes
or dermatitis (e.g.,
erythema, edema,
or hyperkeratosis)
without pain
Skin changes (e.g., peeling,
blisters, bleeding, edema, or
hyperkeratosis) with pain;
limiting instrumental ADL
Severe skin changes (e.g.,
peeling, blisters, bleeding,
edema, or hyperkeratosis)
with pain; limiting self-care
ADL
NA NA
Rash or
desquamation
(maculopapular
rash)
Macules/papules
covering <10 % of
BSAwith or
without symptoms
(e.g., pruritus,
burning, or
tightness)
Macules/papules covering
10–30 % of BSAwith or
without symptoms (e.g.,
pruritus, burning, or
tightness); limiting
instrumental ADL
Macules/papules covering
>30 % of BSAwith or
without associated
symptoms; limiting self-care
ADL
NA NA
Stomatitis
(oral mucositis)
Asymptomatic or mild
symptoms;
intervention not
indicated
Moderate pain, not interfering
with oral intake; modified
diet indicated
Severe pain, interfering with
oral intake
Life-threatening consequences;
urgent intervention indicated
Death
Diarrhea Increase of <4 stools
per day over
baseline; mild
increase in ostomy
output compared
with baseline
Increase of 4–6 stools per day
over baseline; moderate
increase in ostomy output
compared with baseline
Increase of ≥7 stools per day
over baseline; incontinence;
hospitalization indicated;
severe increase in ostomy
output compared with
baseline; limiting self-care
ADL
Life-threatening consequences;
urgent intervention indicated
Death
Hypertension Prehypertension
(systolic BP
120–139 mmHg or
diastolic BP
80–89 mmHg)
Stage 1 hypertension (systolic
BP 140–159 mmHg or
diastolic BP 90–99 mmHg);
medical intervention
indicated; recurrent or
persistent (≥24 h);
symptomatic increase by
>20 mmHg (diastolic) or to
>140/90 mmHg if
previously within normal
limits; monotherapy
indicated
Stage 2 hypertension (systolic
BP >160 mmHg or diastolic
BP ≥100 mmHg); medical
intervention indicated; more
than one drug or more
intensive therapy than
previously used indicated
Life-threatening consequences
(e.g., malignant
hypertension, transient or
permanent neurologic
deficit, or hypertensive
crisis); urgent intervention
indicated
Death
AST increased >ULN to 3×ULN >3 to 5×ULN >5 to 20×ULN >20×ULN NA
ALT increased >ULN to 3×ULN >3 to 5×ULN >5 to 20×ULN >20×ULN NA
Blood bilirubin
increased
>ULN to 1.5×ULN >1.5 to 3×ULN >3 to 10×ULN >10×ULN NA
Fatigue Fatigue relieved by
rest
Fatigue not relieved by rest;
limiting instrumental ADL
Fatigue not relieved by rest;
limiting self-care ADL
NA NA
ADL activities of daily living, ALT alanine aminotransferase, AST aspartate aminotransferase, BP blood pressure, BSA body surface area, HFSR hand–
foot skin reaction, NA not applicable, NCI CTCAE National Cancer Institute Common Terminology Criteria for Adverse Events, ULN upper limit of
normal
840 Support Care Cancer (2014) 22:837–846
dose reduction may be necessary. While the development of
stomatitis is thought to be a drug-related effect in patients
receiving regorafenib, other patient-related factors can in-
crease the intensity of the effect. These include old age, dental
hygiene, nutritional status, associated infections, and dental
pathology [18].
Preventive measures are important in reducing the risk of
stomatitis. Good oral hygiene is crucial and it is important that
patients are appropriately educated about effective dental care
before treatment. Teeth and gums should be cleaned with
fluoride toothpaste and a soft toothbrush or swab (as tolerated)
after meals and before sleep; the mouth should be regularly
rinsed with an alcohol-free mouthwash, saline solution, or
bicarbonate; dentures should be removed and cleaned daily;
and painful stimuli such as hot foods and drinks and spicy
foods should be avoided.
Table 2 The characteristics and management of hand–foot skin reaction
Grade 1 Grade 2 Grade 3
NCI CTCAE version 4.03 [13] Minimal skin changes or dermatitis
(e.g., erythema, edema, or
hyperkeratosis) without pain
Skin changes (e.g., peeling, blisters,
bleeding, edema, or
hyperkeratosis) with pain
Severe skin changes (e.g., peeling,
blisters, bleeding, edema, or
hyperkeratosis) with pain
Clinical presentation Erythema, dysesthesia, paresthesia,
dry or cracked skin, swelling;
does not disrupt ADL
Painful erythema, painful swelling,
thickened hyperkeratotic skin;
limiting ADL (affects normal
activities, e.g., preparing meals,
ability to walk and hold objects)
Callus-like blistering, ulceration,
severe pain; limiting self-care
ADL (inability to work or
perform ADL)
Advice to patients Avoid hot water, alcohol containing
soaps and/or santizers, and
clothing or activities that can
cause friction; wear cotton socks/
gloves at night to prevent injury
and help to retain moisture; cool
skin with cold packs as often as
needed, but intermittently, not
continuously; cushion affected
areas of the feet
As identified for grade 1 As identified for grade 1
Topical treatment Frequent application of emollients
and creams to maintain skin
moisture, prevent cracks, and
provide relief
Clobetasol 0.05 % ointment to
erythematous areas twice daily;
topical analgesics to manage pain
(e.g., lidocaine cream or oral
painkillers); salicylic acid 6 %
can be used for skin scales
Topical therapy for symptomatic
relief; a combination of cortisone
cream and topical antibiotic
Protocol-specified regorafenib dose
modification [9, 11] (patients
requiring >2 dose reductions
[<80 mg] should discontinue
therapy; if toxicity returns to
grade 0–1 after dose reduction,
dose re-escalation is permitted at
the discretion of the investigator;
a more conservative dose-
modification approach, if
medically indicated, is
acceptable)
Any occurrence
Maintain dose level and institute
immediate supportive measures
for symptomatic relief
First occurrence
Consider decreasing dose by 1 dose
level and institute immediate
supportive measures (dose level
1, 160 mg daily; dose level −1,
120 mg daily; dose level −2,
80 mg daily). If no improvement,
interrupt therapy for a minimum
of 7 days, until toxicity resolves
to grade 0–1
No improvement within 7 days or
second occurrence
Interrupt therapy until toxicity
resolves to grade 0–1. When
resuming treatment, treat at
reduced dose level
Third occurrence
Interrupt therapy until toxicity
resolves to grade 0–1. When
resuming treatment, treat at
reduced dose level (minimum
80 mg daily)
Fourth occurrence
Discontinue therapy permanently
First occurrence
Institute immediate supportive
measures. Interrupt therapy for a
minimum of 7 days until toxicity
resolves to grade 0–1. When
resuming treatment, decrease
dose by 1 dose level
Second occurrence
Institute immediate supportive
measures. Interrupt therapy for a
minimum of 7 days until toxicity
resolves to grade 0–1. When
resuming treatment, decrease
dose by 1 additional dose level
Third occurrence
Discontinue treatment permanently
ADL activities of daily living, NCI CTCAE National Cancer Institute Common Terminology Criteria for Adverse Events
Support Care Cancer (2014) 22:837–846 841
If stomatitis occurs, patients should increase the frequency
of mouthwash (e.g., every 1–2 h). In addition to saline-
containing mouthwashes, solutions such as 60 ml mycostatin
(100,000 IU/ml nystatin), 250 ml hexetidine, 10 ml
mepivacaine hydrochloride (10 mg/ml), and 1 g bicarbonate
can be considered. If patients find the mouthwash painful,
they should be advised to use pain medication beforehand
(e.g., viscous lidocaine 2 %, coating agents, and, when need-
ed, systemic approaches following the World Health Organi-
zation pain management ladder). If the patient reports symp-
toms in the throat, and fungal infection is suspected, then
nystatin 5 ml four times daily (swallowed once daily) for
10 days should be recommended. Oral intake of food and
drink should be assessed because pain, dry mouth, and
difficulty swallowing can occur. At grades 3–4, the
mouthwash protocol should be intensified to 8–12 rinses
per day, or every hour, with the addition of analgesics if
considered appropriate. If no improvement is seen after
7 days, then regorafenib should be interrupted until the
stomatitis is reduced to grade 1, at which point treatment
can be reintroduced. Ideally, regorafenib should be
reintroduced at the same dose. Other treatments, such as
coating agents, topical analgesic or anti-inflammatory
agents, topical anesthetics, and alternative mouthwashes
are also available and may be considered.
Diarrhea
Diarrhea is common among patients receiving regorafenib [9,
11]. Five grades of diarrhea are described in the CTCAE
version 4.03 (Table 1) [13]. Although grade 1 diarrhea (an
increase of <4 stools per day over baseline) may not present a
significant problem for patients, grade 2 diarrhea (increase of
4–6 stools per day over baseline) can have a moderate effect
on quality of life, limiting the patient's ability to leave the
house, and grade 3 diarrhea (increase of ≥7 stools per day over
baseline and incontinence) severely affects self-care activities
of daily living (ADL). That said, in our experience, the
prolonged occurrence of grade 2 diarrhea may negatively
affect a patient's quality of life and ADL more than a short-
lasting grade 3 event, and so it is important that patients are
educated about the need to report and manage any occurrence
of diarrhea.
Dietary advice that may minimize the likelihood of diar-
rhea (e.g., ensuring a low intake of fiber) should be given to
patients on initiation of treatment. In order to effectively
manage diarrhea and prevent symptoms from increasing in
severity, patients should be advised to contact their healthcare
team if they have an increase of more than three stools per day.
Patients should also be educated about the variation in stool
form and advised that changes to stool number or consistency
a b
c d
Fig. 1 Hand–foot skin reaction:
a occurring 2 weeks after
initiation of regorafenib therapy;
b 2 weeks later, following
interruption of regorafenib and
reintroduction at a reduced dose
(120 mg) according to protocol-
specified guidelines; c and d
localized hyperkeratotic lesions
on the feet of a patient receiving
regorafenib. Pictures courtesy of
Leiden University Medical
Center, Netherlands, and
University Hospitals Leuven,
Belgium
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do not always indicate diarrhea that requires treatment. The
Bristol stool chart is a useful tool to help explain the variation
to patients—stools are classified into seven types, with types
5–7 tending towards diarrhea [19].
We recommend that patients experiencing diarrhea of
grades 1 and 2 should be advised to take loperamide (two
2-mg tablets) after the first stool and one additional tablet
every 2 h, until 12 h after the last watery stool, for a maximum
of 48 h. It is important to confirm that the patient is experienc-
ing diarrhea, as the use of loperamide could otherwise cause
constipation. In addition, the risk of developing constipation is
increased in a patient already taking opioids for cancer-related
pain. If loperamide does not control the diarrhea, for example
when diarrhea remains grade 3 or higher after the 48-h
loperamide period, the patient is likely to become
dehydrated—the patient should be encouraged to increase
fluid intake and hospital admission should be considered.
Hypertension
In clinical practice, hypertension is common among patients
receiving regorafenib, but, when treated appropriately, the
effect on quality of life is negligible. Hypertension with rego-
rafenib is not cumulative [15]. In our experience, regorafenib,
like other receptor tyrosine kinase inhibitors, can instead be
seen as a toxicity intensifier—it may interfere with the recov-
ery of previous cardiovascular damage, while any direct effect
on cardiovascular function appears to be reversible [20–22].
Regorafenib-associated hypertension is therefore temporary,
and, once regorafenib is discontinued, blood pressure is likely
to decrease to levels that are normal for each individual
patient.
Before initiation of regorafenib treatment, blood pressure
should be checked and controlled if it is found to be elevated.
Blood pressure should then be monitored weekly for the first
two cycles of treatment, and, if detected, hypertension should
be treated. If possible, patients should measure their blood
pressure at home on a daily basis—this helps to identify
patients whose blood pressure is high when visiting the hos-
pital because they are nervous, rather than because they have
persistent hypertension. Table 1 describes, according to
CTCAE version 4.03, five grades of hypertension based on
the levels of systolic and diastolic blood pressure [13]. Blood
pressures exceeding 140/90 mmHg (grade 2 hypertension) are
very common and can be treated with antihypertensive treat-
ment such as angiotensin-converting enzyme (ACE) inhibi-
tors. Blood pressures of grade 3 and higher are less common
but do occur, and, if they are not controlled by ACE inhibitors,
beta blockers can be added as an adjunctive therapy. If hyper-
tension remains a problem, calcium channel blockers can be
added to the ACE inhibitors and beta blockers; because of the
risk of diarrhea, the use of diuretics is discouraged. Recom-
mendations for the management of treatment-emergent
hypertension, as specified in the regorafenib clinical trial
protocols [9, 11], are shown in Table 3.
Liver abnormalities
In our experience, abnormalities in liver function tests can be
very common among patients receiving regorafenib. One case
of fatal liver dysfunction was observed in the CORRECT trial
[9]. Treatment with regorafenib may lead to a higher risk of
severe liver toxicity, with symptoms that may include yellow-
ish discoloration of the skin and the white of the eye, nausea
and vomiting, very dark urine, and changes in sleep patterns.
The liver abnormalities generally occur soon after treatment
initiation, and it is crucial that aspartate aminotransferase
(AST), alanine aminotransferase (ALT), and bilirubin are
measured every 2 weeks for the first two cycles. Table 1 gives
the grading of the laboratory abnormalities according to
CTCAE version 4.03 [13].
We feel that the recommendations for the management of
liver toxicities, through dose modification only, contained in
the CORRECT and GRID protocols are effective in clinical
practice [9, 11]. The recommendations specify that, if AST or
ALT levels greater than five times the upper limit of normal
(ULN) are detected, then regorafenib dosing should be
interrupted until transaminases return to less than three times
ULN or to baseline, at which stage reinitiation of regorafenib
can be considered. If AST or ALT levels reach more than 20
times ULN, or if ASTor ALT levels are more than three times
ULN with concurrent bilirubin more than two times ULN,
treatment should be discontinued. Patients with Gilbert's syn-
drome (who have high baseline levels of bilirubin) with ele-
vated bilirubin should be treated according to the guidelines
for elevated liver enzymes—elevated transaminases need not
be taken into consideration.
Fatigue
In our experience, fatigue is a common and important AE
among patients receiving regorafenib. Cancer-related fatigue
remains one of the most prevalent, distressing, and activity-
limiting symptoms that patients experience, especially in the
later stages of their disease [23]. In the CORRECTand GRID
clinical trials, fatigue was reported in 47.4 and 38.6 % of
patients, respectively [9, 11]. The lower incidence among
patients with GIST may reflect the different prior therapies
and disease histories of GIST and mCRC patients, as well as
the site of disease and any metastases.
Fatigue can affect a patient's quality of life and can be
disabling [23]—at grade 2, fatigue is not relieved by rest and
can limit instrumental ADL (for example, the ability to do
housework or use the telephone); at grade 3, it limits self-care
ADL [13]. The three grades of fatigue, according to the
CTCAE version 4.03, are described in Table 1. However,
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grading a subjective AE such as fatigue can be difficult: in our
experience, some patients may be hesitant to report the occur-
rence or severity of fatigue through a belief that experiencing
toxicities indicates that the treatment is working or because
they expect to experience fatigue due to their age or disease
state; others may contact their healthcare team at the first
indication. It is important to educate patients about the likeli-
hood of experiencing fatigue, and that reporting it early en-
ables them to receive the appropriate advice and management
that may help to prevent it becoming more severe.
For the first two cycles of regorafenib treatment, fatigue
should be monitored weekly. For subsequent cycles, patients
should be monitored for fatigue every 2 weeks and reminded
to contact their healthcare team if fatigue develops or worsens
between visits. If drug-related fatigue is reported, patients
should be advised to take some time out of the day to rest and
recuperate their energy levels. Patients should also be educated
about the potential benefits of exercise—there is clinical evi-
dence that physical exercise may help to improve cancer-related
fatigue [24, 25]. In addition, regorafenib dose modificationmay
be necessary for grade 3 fatigue. Table 3 shows the recom-
mended treatment modifications relevant to fatigue.
Conclusion
Phase III study data have demonstrated that regorafenib can
provide survival benefits in patients with mCRC or GIST
(overall survival and progression-free survival, respectively)
[9, 11]. In our experience using regorafenib in clinical trials
and daily practice, AEs are common but mostly manageable.
Appropriate education, monitoring, and management are es-
sential for reducing the incidence, duration, and severity of
regorafenib-associated AEs, and we have provided a checklist
(Table 4) to aid the prompt and appropriate management of
these AEs. We recommend attempting to manage the effect
before dose reduction or interruption. If dose modification is
deemed advisable, the protocols of the phase III regorafenib
Table 3 Protocol-specified recommendations for the management of hypertension and other toxicities related to regorafenib (except HFSR and liver
function test abnormalities) [9, 11]
Grade
of
eventa
Hypertension Toxicities related to study drug
(except hypertension, HFSR, and liver function test abnormalities)
Grade
1
Consider increasing the frequency of BP monitoring Treat on time, no dose change
Grade
2
Asymptomatic grade 2—recurrent or persistent (≥24 h) increase by
>20 mmHg (diastolic) or to >150/100 mmHg
Begin antihypertensive therapy (titrated to effect) and continue
regorafenib.
If diastolic BP is not controlled (≤100 mmHg) with the addition of
antihypertensive therapy, reduce regorafenib by 1 dose level (dose level
1, 160 mg daily; dose level −1, 120 mg daily; dose level −2, 80 mg
daily)b,
Symptomatic grade 2—any increase by >20 mmHg (diastolic) or to
>150/100 mmHg, associated with symptoms
Interrupt regorafenib until symptoms resolve and diastolic BP
≤100 mmHgb; also treat patient with antihypertensive medications
(titrated to effect).
If diastolic BP is not controlled ≤100 mmHg with the addition of
antihypertensive therapy, reduce regorafenib by 1 dose levelc
Treat on time, no dose change
Grade
3
Interrupt regorafenib until symptoms resolve and diastolic BP
≤100 mmHgb; increase current antihypertensive medication(s)/add
additional antihypertensive medications. When regorafenib is restarted,
reduce regorafenib by 1 dose levelc.
If diastolic BP is not controlled (≤100 mmHg) with the addition of more
intensive therapy, reduce another dose leveld
Interrupt dose until grade ≤2; reduce regorafenib by 1 dose level
(dose level 1, 160 mg daily; dose level −1, 120 mg daily; dose
level −2, 80 mg daily); if toxicity remains at grade ≤2, dose re-
escalation can be considered at the discretion of the treating
investigator. If dose is re-escalated and toxicity (grade ≥3)
recurs, institute permanent dose reduction
Grade
4
Discontinue therapy Interrupt dose until grade ≤2; reduce regorafenib by 1 dose level.
Permanent discontinuation can be considered at treating
investigator's discretion
BP blood pressure, HFSR hand–foot skin reaction
a See Table 1 for description of National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03 grading
b Patients requiring a delay of >4 weeks should discontinue therapy
c If BP remains controlled for at least one full cycle, dose re-escalation is permitted at the investigator's discretion
d Patients requiring >2 dose reductions (<80 mg) should discontinue therapy
844 Support Care Cancer (2014) 22:837–846
Table 4 Adverse event management checklist for those involved in the
treatment and monitoring of patients receiving regorafenib for metastatic
colorectal cancer or advanced gastrointestinal stromal tumor
Adverse
event
Recommendation Completed
General • Stress the importance of communication
between patients and the healthcare team
□
• Emphasize that early detection and
therapeutic intervention (where
appropriate) can lessen the severity of
adverse events and reduce the likelihood
that regorafenib dose modification will be
required
□
• Advise patients to keep a diary of their
physical well-being to ensure that they do
not forget or overlook changes between
visits
□
HFSR • Carry out a full-body skin examination
before treatment
□
• Soften and remove calluses before and
during treatment
□
• Actively monitor every week during the
first two cycles, then every 4 weeks from
cycle 3
□
• Encourage patients and caregivers to
monitor for potential symptoms of HFSR
□
• Educate patients about appropriate steps to
minimize or prevent HFSR, e.g., using
moisturizers or emollients and avoiding
pressure on the skin
□
• If HFSR is painful, advise patients to cool
the skin with cold packs and treat with
analgesics
□
• Refer to the protocol-specified guidelines
for effective dose modification advice
when necessary [9, 11]
□
Rash or
desquama-
tion
• Monitor every week during the first two
cycles, then every 4 weeks from cycle 3
□
• Recommend preventive measures, such as
the use of emollients and the avoidance of
harsh soaps, extreme temperatures, and
direct sunlight
□
• If rash occurs, manage with antihistamine
and a corticosteroid-containing ointment
□
Stomatitis • Educate patients about effective dental care
and the need for good oral hygiene
□
• Encourage patients to clean teeth and gums
with fluoride toothpaste and a soft
toothbrush or swab after meals and before
sleep
□
• Recommend regular use of an alcohol-free
mouthwash, saline solution, or
bicarbonate, as a preventive measure
□
• If stomatitis occurs, advise patients to
increase the frequency of saline
mouthwash, e.g., every 1–2 h.
Mouthwash solutions such as mycostatin
60 ml (nystatin 100,000 IU/ml),
hexetidine 250 ml, mepivacaine
hydrochloride 10 ml (10 mg/ml), and
bicarbonate 1 g can also be considered
□
• If mouthwash is painful, advise patients to
use pain medication beforehand (e.g.,
viscous lidocaine 2 %, coating agents, or
□
Table 4 (continued)
Adverse
event
Recommendation Completed
systemic approaches following the World
Health Organization pain management
ladder)
• Assess oral intake of food and drink □
• Interrupt regorafenib dose until stomatitis
is reduced to grade ≤2 if necessary—
ideally, regorafenib should then be
reintroduced at the same dose
□
Diarrhea • Educate patients about the likelihood of
changes to stool frequency and/or
consistency, and the need to report and
manage any occurrence of diarrhea
□
• Provide dietary advice to helpminimize the
risks of diarrhea
□
• Advise patients to contact their healthcare
team if stool consistency or frequency
changes during treatment
□
• Advise patients who experience grade 1 or
2 diarrhea to take loperamide (two 2 mg
tablets after the first stool and then one
tablet every 2 h for a maximum of 48 h)
□
• If loperamide does not control the diarrhea,
consider hospital admission and
encourage the patient to increase fluid
intake
□
Hypertension • Check blood pressure before initiation of
regorafenib therapy, and control if
elevated
□
•Monitor blood pressure weekly for the first
two cycles, and treat with
antihypertensive therapy if necessary
□
• If possible, patients should monitor their
blood pressure at home daily
□
• Refer to the protocol-specified guidelines
for appropriate dose modifications [9, 11]
□
Liver
abnormali-
ties
• Check AST, ALT, and bilirubin every
2 weeks for the first two cycles
□
• If liver toxicity is detected, refer to the
protocol-specified guidelines for
appropriate dose modifications
□
Fatigue • Ensure that patients are aware of the
likelihood of fatigue, the potential
negative effects on ADL and quality of
life, and the benefits of early reporting
□
•Monitor weekly for the first two cycles and
at every visit (every 2 weeks) thereafter
□
• Educate patients about the importance of
informing the healthcare team if fatigue
develops or worsens between visits
□
• Recommend that patients take time out of
the day to rest and recuperate energy
levels
□
• Inform patients about the potential benefits
of exercise on fatigue
□
• If necessary, delay or reduce regorafenib
dose until fatigue has reduced
□
ADL activities of daily living, ALT alanine aminotransferase, AST aspar-
tate aminotransferase, HFSR hand–foot skin reaction
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trials [9, 11] provide clear guidance on approaches for the
different AEs, including treatment interruption until the AE
has resolved followed by reintroduction of regorafenib at a
lower dose (minimum 80 mg daily). If the patient is able to
tolerate the reduced dose without recurrence of the AE, we
recommend re-escalating the dose if possible.
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